Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

Impact · against what's priced in

The approval of Hibsago is a positive catalyst for Ionis and GSK, as it provides a new revenue stream not currently accounted for in the market's skeptical valuation of Ionis. For Ionis, this adds a tangible win to a price that has largely discounted its pipeline following recent cardiovascular setbacks.

IONS+0.40

Challenges what's priced in

The price assumes